New patent expiration for Endo Pharms drug OPANA ER

Opana ER, marketed by Endo Pharms, is under five patent protections and has faced six Paragraph IV challenges. The drug has 169 patent family members across 32 nations. The generic ingredient in OPANA ER is oxymorphone hydrochloride.